A compound is represented by Structural Formula (I):
or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
一种化合物由结构式(I)表示,或其药学上可接受的盐。一种制药组合物包括由结构式(I)表示的化合物或其药学上可接受的盐。一种治疗需要的受体的方法包括向受体施用结构式(I)表示的化合物或其药学上可接受的盐的治疗有效量。该受体患有2型糖尿病;与糖尿病性肾病相关的肾肥大或增生;Tay-Sachs病;Gaucher病;或Fabry病。在需要的受体中,分别降低血浆TNF-α,降低血糖
水平,降低糖化血红蛋白
水平,抑制
葡萄糖酰胺合成酶和降低
糖脂浓度的方法包括向受体施用结构式(I)表示的化合物或其药学上可接受的盐的治疗有效量。